Prevalence and impact of hypogonadism in cancer patients with severe muscle wasting in phase IIb enobosarm trial

Autor:	Mary Ann Johnston, Adrian S. Dobs, Mitchell S. Steiner, Ronald A. Morton, Shontelle Dodson, Michael L. Hancock
Rok vydání:	2012
Předmět:	Cancer Research medicine.medical_specialty business.industry Cancer medicine.disease Advanced cancer chemistry.chemical_compound Oncology chemistry Weight loss Internal medicine medicine Presentation (obstetrics) Enobosarm medicine.symptom business Wasting
Zdroj:	Journal of Clinical Oncology. 30:e19582-e19582
ISSN:	1527-7755 0732-183X
Popis:	e19582 Background: Hypogonadism has been associated with weight loss and poor outcomes in cancer patients. Up to 50% of males with advanced cancer are hypogonadal at presentation or during the course of treatment. Wasting in cancer patients has also been associated with a decline in physical function and performance status and has major public health significance. We conducted a Phase IIb randomized, double blind, placebo controlled, multi-center study to evaluate the effect of enobosarm on muscle wasting and physical function in cancer patients. Methods: Patients (n=159) were randomized to oral enobosarm (1 or 3 mg) or placebo daily for 16 wks. Patients were males >45 y and postmenopausal females, had ≥2% weight loss in the 6 mths prior to randomization, BMI
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7175442a01d88950963aa2761493c839 https://doi.org/10.1200/jco.2012.30.15_suppl.e19582 Zobrazit plný text záznamu